US: 800.298.5699
Int'l: +1.240.747.3093
 
Matching geography
Reports matching your search in:
 
 
Join Alert Me now!
Receive bi-weekly email alerts on new market research

Sign up today!
 

CNS/Neurology: market research reports

RSS Feeds

CNS/Neurology market research reports and industry analysis

3  4  5  6    8    10  11  12  
Tension -Type Headache Global Clinical Trials Review, H1, 2013
4/30/2013 | published by: GlobalData
... report provides elemental information and data relating to the clinical trials on Tension -Type Headache. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across ...  |  read more...
$2,500.00
Essential Tremor – Pipeline Review, H1 2013
4/30/2013 | published by: Global Markets Direct
... for Essential Tremor, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Essential Tremor. Essential Tremor - Pipeline Review, Half Year ...  |  read more...
$2,000.00
Global Deep Brain Stimulator Market 2012-2016
4/26/2013 | published by: Infiniti Research Limited - TechNavio
... this market growth is the rapidly increasing awareness about deep brain stimulation devices in the US. The Global Deep Brain Stimulator market has also been witnessing the emergence of less invasive and non-invasive treatments. However, ...  |  read more...
$2,000.00
The Depression Market Forecast to 2021
4/25/2013 | published by: Datamonitor
... five major EU markets in 2012 Features and benefits Excel and pdf with forecasts through to 2021 covering the US, Japan, and 5 major EU markets, to allow you to assess future growth opportunities Analysis ...  |  read more...
$8,000.00
Anorexia Nervosa Global Clinical Trials Review, H1, 2013
4/22/2013 | published by: GlobalData
... and data relating to the clinical trials on Anorexia Nervosa. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers ...  |  read more...
$2,500.00
Dyslexia Global Clinical Trials Review, H1, 2013
4/12/2013 | published by: GlobalData
... relating to the clinical trials on Dyslexia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage ...  |  read more...
$2,500.00
Disease and Therapy Review: Generalized Anxiety Disorder (GAD)
4/10/2013 | published by: Timely Data Resources, Inc.
... on diagnosis, and an overview of treatment. Dosing and treatment cost information is provided for various treatment types. General information on the anxiety market, as well as sales of leading drugs and therapies are provided.  |  read more...
$950.00
Attention Deficit Hyperactivity Disorder (ADHD) Global Clinical Trials Review, H1, 2013
3/31/2013 | published by: GlobalData
... Disorder (ADHD) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Attention Deficit Hyperactivity Disorder (ADHD). It includes an overview of the trial numbers and their recruitment status ...  |  read more...
$2,500.00
Anorexia Nervosa – Pipeline Review, H1 2013
3/28/2013 | published by: Global Markets Direct
... for Anorexia Nervosa, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Anorexia Nervosa. Anorexia Nervosa - Pipeline Review, Half Year ...  |  read more...
$2,000.00
Biomaterials Market [By Products (Polymers, Metals, Ceramics, Natural Biomaterials) & Applications (Cardiovascular, Orthopedic, Dental, Plastic Surgery, Wound Healing, Tissue Engineering, Ophthalmology, Neurology Disorders)] – Global Forecasts to 2017
3/28/2013 | published by: MarketsandMarkets
... Chinese, and Aztecs used gold for dental applications. Biomaterials, which are also biocompatible, have since been adapted, improvised, and technically enabled to improve body functions and replace damaged tissues. They have evolved to include biodegradable ...  |  read more...
$4,650.00
Brain Hemorrhage – Pipeline Review, H1 2013
3/28/2013 | published by: Global Markets Direct
... for Brain Hemorrhage, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Brain Hemorrhage. Brain Hemorrhage - Pipeline Review, Half Year ...  |  read more...
$2,000.00
2013 U.S. Patient care - Nervous system & sense organ disorders sold through Offices of physicians-Product & Services Report
3/15/2013 | published by: Barnes Reports
... report features 2013 current and 2014 forecast estimates on the sales of Patient care - Nervous system & sense organ disorders sold through Offices of physicians nationally and for all 50 U.S. States and up ...  |  read more...
$199.00
2013 U.S. Patient care - Nervous system & sense organ disorders sold through Medical & surgical hospitals-Product & Services Report
3/15/2013 | published by: Barnes Reports
... The report features 2013 current and 2014 forecast estimates on the sales of Patient care - Nervous system & sense organ disorders sold through Medical & surgical hospitals nationally and for all 50 U.S. States ...  |  read more...
$199.00
Lemtrada (Multiple Sclerosis) - Forecast and Market Analysis to 2022
3/1/2013 | published by: GlobalData
... a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and neurodegeneration within the central nervous system. With curative therapy still elusive, current disease management is dependent on life-long pharmacotherapy with disease-modifying therapies (DMT). ...  |  read more...
$3,495.00
BG-12 (Multiple Sclerosis) - Forecast and Market Analysis to 2022
3/1/2013 | published by: GlobalData
... a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and neurodegeneration within the central nervous system. With curative therapy still elusive, current disease management is dependent on life-long pharmacotherapy with disease-modifying therapies (DMT). ...  |  read more...
$3,495.00
Pain Management Treatment Markets
3/1/2013 | published by: TriMark Publications
... segments of the central nervous system (CNS) therapies market. Pain Management Treatment Markets focuses on the role of pain management drugs in clinical use and in drug development for acute pain, chronic pain, neuropathic path ...  |  read more...
$3,400.00
Siponimod (Multiple Sclerosis) - Forecast and Market Analysis to 2022
3/1/2013 | published by: GlobalData
... a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and neurodegeneration within the central nervous system. With curative therapy still elusive, current disease management is dependent on life-long pharmacotherapy with disease-modifying therapies (DMT). ...  |  read more...
$3,495.00
NU-100 (Multiple Sclerosis) - Forecast and Market Analysis to 2022
3/1/2013 | published by: GlobalData
... a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and neurodegeneration within the central nervous system. With curative therapy still elusive, current disease management is dependent on life-long pharmacotherapy with disease-modifying therapies (DMT). ...  |  read more...
$3,495.00
Daclizumab (Multiple Sclerosis) - Forecast and Market Analysis to 2022
3/1/2013 | published by: GlobalData
... a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and neurodegeneration within the central nervous system. With curative therapy still elusive, current disease management is dependent on life-long pharmacotherapy with disease-modifying therapies (DMT). ...  |  read more...
$3,495.00
Copaxone (Multiple Sclerosis) - Forecast and Market Analysis to 2022
3/1/2013 | published by: GlobalData
... a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and neurodegeneration within the central nervous system. With curative therapy still elusive, current disease management is dependent on life-long pharmacotherapy with disease-modifying therapies (DMT). ...  |  read more...
$3,495.00
Central Nervous System (CNS) Biomarkers: Technologies and Global Markets
3/1/2013 | published by: BCC Research
... be used to diagnose or predict disease, monitor disease progression, and predict treatment response. Analyses of global market trends, with data from 2010 through 2012, and projections of compound annual growth rates (CAGRs) through 2017. ...  |  read more...
$6,650.00
Rebif (Multiple Sclerosis) - Forecast and Market Analysis to 2022
3/1/2013 | published by: GlobalData
... a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and neurodegeneration within the central nervous system. With curative therapy still elusive, current disease management is dependent on life-long pharmacotherapy with disease-modifying therapies (DMT). ...  |  read more...
$3,495.00
Tysabri (Multiple Sclerosis) - Forecast and Market Analysis to 2022
3/1/2013 | published by: GlobalData
... a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and neurodegeneration within the central nervous system. With curative therapy still elusive, current disease management is dependent on life-long pharmacotherapy with disease-modifying therapies (DMT). ...  |  read more...
$3,495.00
Gilenya (Multiple Sclerosis) - Forecast and Market Analysis to 2022
3/1/2013 | published by: GlobalData
... a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and neurodegeneration within the central nervous system. With curative therapy still elusive, current disease management is dependent on life-long pharmacotherapy with disease-modifying therapies (DMT). ...  |  read more...
$3,495.00
Aubagio (Multiple Sclerosis) - Forecast and Market Analysis to 2022
3/1/2013 | published by: GlobalData
... a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and neurodegeneration within the central nervous system. With curative therapy still elusive, current disease management is dependent on life-long pharmacotherapy with disease-modifying therapies (DMT). ...  |  read more...
$3,495.00
3  4  5  6    8    10  11  12  
 
Our Clients